CoChat
Sign Up
Cited by 29

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Inactivation of mTORC2 in macrophages is a signature of colorectal cancer that promotes tumorigenesis

Katholnig, Karl, Schütz, Birgit, Fritsch, Stephanie D., Schörghofer, David, Linke, Monika, Sukhbaatar, Nyamdelger, Matschinger, Julia M., Unterleuthner, Daniela, Hirtl, Martin, Lang, Michaela, Herac, Merima, Spittler, Andreas, Bergthaler, Andreas, Schabbauer, Gernot, Bergmann, Michael, Dolznig, Helmut, Hengstschläger, Markus, Magnuson, Mark A., Mikula, Mario, Weichhart, Thomas·2019·JCI Insight
DOI 10.1172/jci.insight.124164
Open this paper in CoChat — free account

Abstract

The mechanistic target of rapamycin complex 2 (mTORC2) is a potentially novel and promising anticancer target due to its critical roles in proliferation, apoptosis, and metabolic reprogramming of cancer cells. However, the activity and function of mTORC2 in distinct cells within malignant tissue in vivo is insufficiently explored. Surprisingly, in primary human and mouse colorectal cancer (CRC) samples, mTORC2 signaling could not be detected in tumor cells. In contrast, only macrophages in tumor-adjacent areas showed mTORC2 activity, which was downregulated in stromal macrophages residing within human and mouse tumor tissues. Functionally, inhibition of mTORC2 by specific deletion of Rictor in macrophages stimulated tumorigenesis in a colitis-associated CRC mouse model. This phenotype was driven by a proinflammatory reprogramming of mTORC2-deficient macrophages that promoted colitis via the cytokine SPP1/osteopontin to stimulate tumor growth. In human CRC patients, high SPP1 levels and low mTORC2 activity in tumor-associated macrophages correlated with a worsened clinical prognosis. Treatment of mice with a second-generation mTOR inhibitor that inhibits mTORC2 and mTORC1 exacerbated experimental colorectal tumorigenesis in vivo. In conclusion, mTORC2 activity is confined to macrophages in CRC and limits tumorigenesis. These results suggest activation but not inhibition of mTORC2 as a therapeutic strategy for colitis-associated CRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.124164

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 64

  1. 10.1016/j.cell.2017.02.004 · DOI · Paper page
  2. 10.1016/j.gde.2012.12.005 · DOI
  3. 10.1016/j.cell.2012.03.017 · DOI · Paper page
  4. 10.1002/1873-3468.12711 · DOI
  5. 10.1038/nri3901 · DOI
  6. 10.4161/cc.10.14.16586 · DOI
  7. 10.1038/emboj.2008.119 · DOI
  8. 10.1016/j.ccell.2017.11.011 · DOI
  9. 10.1158/1541-7786.MCR-16-0256 · DOI
  10. 10.1016/j.molcel.2017.05.030 · DOI
  11. 10.1016/j.tem.2014.04.002 · DOI
  12. Kühl, 2015, Diversity of Intestinal Macrophages in Inflammatory Bowel Diseases, Front Immunol, 6, 10.3389/fimmu.2015.00613 · DOI
  13. 10.1056/NEJMra020831 · DOI
  14. 10.1038/nrgastro.2015.150 · DOI · Paper page
  15. 10.1038/nri1132 · DOI
  16. 10.1016/j.cell.2010.01.025 · DOI · Paper page
  17. 10.1007/s11888-017-0373-6 · DOI
  18. 10.1016/j.it.2013.02.001 · DOI
  19. 10.1038/nri2891 · DOI
  20. 10.1042/BST20130032 · DOI
  21. 10.4049/jimmunol.1200069 · DOI
  22. 10.1371/journal.pone.0095432 · DOI · Paper page
  23. Hallowell, 2017, mTORC2 signalling regulates M2 macrophage differentiation in response to helminth infection and adaptive thermogenesis, Nat Commun, 8, 10.1038/ncomms14208 · DOI · Paper page
  24. 10.1016/j.immuni.2016.09.016 · DOI
  25. Babaev, 2018, Loss of Rictor in Monocyte/Macrophages Suppresses Their Proliferation and Viability Reducing Atherosclerosis in LDLR Null Mice, Front Immunol, 9, 10.3389/fimmu.2018.00215 · DOI
  26. 10.1016/j.celrep.2017.08.046 · DOI
  27. Feldman, 2009, Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2, PLoS Biol, 7, 10.1371/journal.pbio.1000038 · DOI
  28. 10.1158/0008-5472.CAN-09-0299 · DOI
  29. 10.1016/j.tips.2014.11.004 · DOI
  30. 10.1016/S0140-6736(08)61039-9 · DOI · Paper page
  31. 10.1016/j.cmet.2014.01.001 · DOI · Paper page
  32. 10.2174/1568009616666151113120830 · DOI
  33. 10.2174/092986711796391651 · DOI
  34. 10.4161/cc.8.23.10070 · DOI
  35. 10.1007/s10495-014-1066-0 · DOI
  36. 10.1007/978-1-61779-430-8_29 · DOI
  37. 10.1111/j.1349-7006.2003.tb01386.x · DOI
  38. Chassaing, 2014, Dextran sulfate sodium (DSS)-induced colitis in mice, Curr Protoc Immunol, 104, 10.1002/0471142735.im1525s104 · DOI
  39. Thaker, 2012, Modeling colitis-associated cancer with azoxymethane (AOM) and dextran sulfate sodium (DSS), J Vis Exp, 10.3791/4100 · DOI
  40. 10.1038/sj.bjp.0704633 · DOI
  41. 10.1016/j.matbio.2014.03.001 · DOI
  42. 10.1007/s12079-009-0068-0 · DOI
  43. 10.1371/journal.pone.0135552 · DOI
  44. 10.1097/00054725-200608000-00015 · DOI
  45. Thalmann, 1999, Osteopontin: possible role in prostate cancer progression, Clin Cancer Res, 5, 2271
  46. 10.1038/nature11252 · DOI · Paper page
  47. 10.1073/pnas.0902232106 · DOI
  48. 10.1074/jbc.M111.258053 · DOI
  49. 10.4049/jimmunol.1402551 · DOI
  50. 10.1007/s12026-010-8179-5 · DOI
  51. Clemente, 2016, Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases, J Immunol Res, 2016, 10.1155/2016/7675437 · DOI
  52. 10.1136/gut.2004.048298 · DOI
  53. 10.1073/pnas.1316447111 · DOI
  54. 10.1111/j.1582-4934.2008.00428.x · DOI
  55. 10.1016/0169-5002(95)00595-1 · DOI
  56. 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3 · DOI
  57. 10.1038/onc.2013.184 · DOI
  58. 10.1016/j.ccell.2016.08.002 · DOI
  59. Ishigamori, 2017, Osteopontin Deficiency Suppresses Intestinal Tumor Development in Apc-Deficient Min Mice, Int J Mol Sci, 18, 10.3390/ijms18051058 · DOI
  60. 10.1172/JCI123360 · DOI
  61. 10.1016/j.devcel.2006.08.013 · DOI
  62. 10.1023/A:1008942828960 · DOI · Paper page
  63. Gupta, 2014, Analysis of Intestinal Permeability in Mice, Bio-protocol, 4, 10.21769/BioProtoc.1289 · DOI
  64. 10.1016/j.ajpath.2011.03.015 · DOI

Cited by

Sorted by citations

See all 29

Metadata

Authors
Katholnig, K., Schütz, B., Fritsch, S. D., Schörghofer, D., Linke, M., Sukhbaatar, N., Matschinger, J. M., Unterleuthner, D., Hirtl, M., Lang, M., Herac, M., Spittler, A., Bergthaler, A., Schabbauer, G., Bergmann, M., Dolznig, H., Hengstschläger, M., Magnuson, M. A., Mikula, M., & Weichhart, T.
Affiliations
  • Center of Pathobiochemistry and Genetics, Institute of Medical Genetics,
  • Department of Internal Medicine III, Division of Gastroenterology and Hepatology,
  • Clinical Institute of Pathology, and
  • Core Facility Flow Cytometry & Surgical Research Laboratories, Medical University of Vienna, Vienna, Austria.
  • CeMM Research Center for Molecular Medicine, Austrian Academy of Sciences, Vienna, Austria.
  • Institute for Physiology, Center for Physiology and Pharmacology, and
  • Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria.
  • Department of Molecular Physiology and Biophysics and Center for Stem Cell Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
ORCID
Venue
JCI Insight
Publisher
American Society for Clinical Investigation
Published
2019-10-17
Volume
4
Issue
20
ISSN
2379-3708
DOI
10.1172/jci.insight.124164
Cited by
29
References
2
Language
en
Funders
  • FWF (P30857-B28,P27701-B20, P25336-B13)
  • WWTF (LS18-058)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inactivation of mTORC2 in macrophages is a signature of colorectal cancer that promotes tumorigenesis. https://app.cochat.ai/papers/10.1172/jci.insight.124164
The paper
Katholnig, K., Schütz, B., Fritsch, S. D., Schörghofer, D., Linke, M., Sukhbaatar, N., Matschinger, J. M., Unterleuthner, D., Hirtl, M., Lang, M., Herac, M., Spittler, A., Bergthaler, A., Schabbauer, G., Bergmann, M., Dolznig, H., Hengstschläger, M., Magnuson, M. A., Mikula, M., & Weichhart, T. (2019). Inactivation of mTORC2 in macrophages is a signature of colorectal cancer that promotes tumorigenesis. JCI Insight. https://doi.org/10.1172/jci.insight.124164